PEPG

In the past six months, PepGen's stock price was impacted by several events. On March 30, 2026, the company announced topline results from the Phase 2 FREEDOM2-DM1 study, which led to a stock price drop due to disappointing splicing correction data. On March 4, 2026, the U.S. FDA placed a partial clinical hold on the FREEDOM2 trial, causing the stock to decline. On November 12, 2025, PepGen reported positive results from the FREEDOM study and announced a $115 million financing round.